Renovaro INC 8-K filings

Lunai Bioworks CEO David Weinstein's letter to shareholders highlights advancements in its AI-driven biodefense platform, precision neurology pipeline, and ongoing litigation against alleged market manipulation.

Lunai Bioworks, Inc. has received confirmation from Nasdaq that it has regained compliance with the minimum bid price rule, subject to a one-year monitoring period.

Lunai Bioworks, Inc. is implementing a 1-for-8 reverse stock split to increase its share price and comply with Nasdaq listing requirements.

Lunai Bioworks, Inc. announced that its stockholders approved a reverse stock split proposal at a special meeting held on May 8, 2026.

Lunai Bioworks discloses an additional Nasdaq staff determination regarding non-compliance with market value requirements while pursuing a reverse stock split.

Lunai Bioworks acquired a multi-jurisdictional patent portfolio from Oncotelic and Pelerin Therapeutics in exchange for $20 million in Series B Convertible Preferred Stock.

Lunai Bioworks has rescheduled its Special Meeting of Stockholders to May 8, 2026, to ensure sufficient time for broker discretionary voting and quorum attainment.

Lunai Bioworks strengthens its CNS pipeline with a $20 million acquisition of blood-brain barrier delivery technology and reduces $828,770 in debt through an equity exchange.

Lunai Bioworks Inc. has temporarily furloughed U.S. and Canadian employees to preserve liquidity while seeking additional financing.

Lunai Bioworks Inc. has secured a hearing with the Nasdaq Hearings Panel to appeal a delisting determination, temporarily staying the action.

Lunai Bioworks, Inc. received a notice from Nasdaq regarding the delisting of its securities due to non-compliance with the minimum bid price rule.

Lunai Bioworks, Inc. entered into an At-the-Market Sales Agreement with Dawson James Securities, Inc. to offer and sell up to $11.70 million of common stock.

Lunai Bioworks Inc. announced a private placement of common stock and warrants to an accredited investor, raising $3.13 million for working capital.

Lunai Bioworks Inc. announced it has re-established compliance with Nasdaq's annual meeting requirement, resolving a previous listing deficiency.

Lunai Bioworks, Inc. announced that its shareholders approved all four proposals, including director elections and executive compensation, at the annual meeting held on October 31, 2025.

Lunai Bioworks received a Nasdaq notice for failing to meet the $35 million minimum Market Value of Listed Securities requirement, initiating a 180-day compliance period.

Lunai Bioworks announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on The Nasdaq Capital Market.

Lunai Bioworks, an AI-powered biodefense company, will effect a 1-for-10 reverse stock split to meet Nasdaq's minimum bid price requirement.

Lunai Bioworks' indirect subsidiary, Gedi Cube B.V., was declared bankrupt by the Court of Amsterdam, leading to an expected material asset impairment for Lunai.

Renovaro Inc. has officially changed its corporate name to Lunai Bioworks Inc., effective August 20, 2025, while retaining its Nasdaq ticker symbol RENB.

Renovaro Inc. received an extension from Nasdaq until October 31, 2025, to hold its annual shareholder meeting and regain compliance with listing rules.

Renovaro Inc. announced the resignation of Maurice van Tilburg as Chairman of the Board, effective August 22, 2025, due to a new leadership role in an unrelated sector.

Renovaro Inc. has received a notice from Nasdaq regarding non-compliance with listing rules for failing to hold its annual shareholder meeting, potentially leading to delisting if a compliance plan is not accepted.

Renovaro Inc. announced the conversion of approximately $9.7 million in senior debt into equity, issuing 53.6 million shares, to strengthen its financial position and advance AI-driven precision medicine.

Maurice van Tilburg has resigned as CEO of Renovaro Inc.'s indirect subsidiary, GEDi Cube B.V., effective May 30, 2025, though he will remain on Renovaro's Board of Directors.

Renovaro Inc. received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement for continued listing.

Renovaro Inc. successfully acquired Biosymetrics, Inc. through a merger, issuing 15 million shares of its common stock to Biosymetrics' former stockholders.

Renovaro extends its letter of intent to acquire Predictive Oncology, increasing its investment through additional share purchases and amending the original agreement.

Renovaro Biosciences Inc. and BioSymetrics have entered into a definitive merger agreement aimed at advancing AI-driven biomarker discovery and precision medicine.

Renovaro Inc. announced that it will restate its previously issued financial statements for multiple periods due to material misstatements related to certain warrants.